Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Accounts Payables: 2020-2024

Historic Accounts Payables for Biofrontera (BFRI) over the last 5 years, with Dec 2024 value amounting to $4.3 million.

  • Biofrontera's Accounts Payables rose 40.77% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 40.77%. This contributed to the annual value of $4.3 million for FY2024, which is 4.77% down from last year.
  • According to the latest figures from FY2024, Biofrontera's Accounts Payables is $4.3 million, which was down 4.77% from $4.5 million recorded in FY2023.
  • Biofrontera's Accounts Payables' 5-year high stood at $10.9 million during FY2022, with a 5-year trough of $2.7 million in FY2020.
  • Its 3-year average for Accounts Payables is $6.5 million, with a median of $4.5 million in 2023.
  • As far as peak fluctuations go, Biofrontera's Accounts Payables spiked by 256.76% in 2021, and later crashed by 58.70% in 2023.
  • Over the past 5 years, Biofrontera's Accounts Payables (Yearly) stood at $2.7 million in 2020, then surged by 256.76% to $9.7 million in 2021, then increased by 12.53% to $10.9 million in 2022, then tumbled by 58.70% to $4.5 million in 2023, then declined by 4.77% to $4.3 million in 2024.